Celularity Inc., a clinical-stage biotechnology company based in Florham Park, New Jersey, has announced the appointment of Dale A. Sander as its new Chief Financial Officer and EVP. The leadership transition follows the resignation of Andrew E. Pecora, who held the CFO role since 2023 and will now resume his previous position as President of the company’s therapeutics division.
Sander previously served as CFO at Humacyte and brings over 30 years of experience in financial and operational leadership within the life sciences sector. Celularity said that his appointment comes at a pivotal time as the company continues to develop off-the-shelf placental-derived cell therapies for cancer, degenerative diseases, and infectious diseases.
“Dale’s extensive experience with public and private biotech companies, as well as his track record in raising capital, makes him an excellent fit for our leadership team,” said CEO Robert J. Hariri. The company emphasized that Sander will be instrumental in driving its financial strategy and supporting ongoing and future clinical development programs.
Andrew Pecora, who led Celularity through a period of financial restructuring, will continue to serve on the board of directors. The company claims that this transition strengthens both its executive bench and therapeutic focus as it prepares for potential commercial pathways.
